Současné postavení telemedicíny v péči o pacienty s idiopatickými střevními záněty

English version

Authors: I. Romanko
Authors‘ workplace: Joint Admission of the General University Hospital for People with Medical Problems, Clinic of Anesthesiology, Resuscitation and Intensive Medicine, 1st Faculty of Medicine and General University Hospital in Prague
Published in: Gastroent Hepatol 2017; 71(4): 315-322
Category: IBD: Review Article
doi: https://doi.org/10.14735/amgh2017315

Overview

Specializovaná centra pro léčbu chronických onemocnění, jako jsou idiopatické střevní záněty (IBD – inflammatory bowel disease), jsou často na hranici svých možností při sledování a léčbě pacientů s těmito chorobami. Důvodem je narůstající incidence Crohnovy nemoci a ulcerózní kolitidy a zvyšující se podíl nemocných s těžším průběhem zánětu, kteří vyžadují komplexní péči. V současné době již existují různé způsoby, které umožnují zjednodušení a urychlení komunikace pacienta s příslušným IBD centrem. Využívají se k tomu moderní informační technologie, jako např. webové rozhraní, virtuální kliniky, video komunikace, chytré telefony nebo e-mail. Uplatněním těchto a dalších technologií v medicíně se zabývá telemedicína. V současnosti se stala tématem mnoha diskuzí a výzkumů a stoupá úroveň důkazů o její vhodnosti, propěšnosti a cenové výhodnosti pro lékaře, pacienty i systém zdravotní péče. Tento článek poukazuje na aktuální studie a přehledy pojednávající o současné a budoucí roli telemedicíny, neboli „eHealth“, v péči o IBD pacienty a nabízí pohled na to, jak by využití těchto technologií mělo/mohlo vypadat tak, aby se stali důležitou součástí denní klinické praxe.

Klíčová slova:
idiopatické střevní záněty – Crohnova nemoc – ulcerózní kolitida – telemedicína – eHealth

Autoři deklarují, že v souvislosti s předmětem studie nemají žádné komerční zájmy.

Redakční rada potvrzuje, že rukopis práce splnil ICMJE kritéria pro publikace zasílané do biomedicínských časopisů.

Doručeno:
17. 5. 2017

Přijato:
31. 7. 2017

Sources

1. Vora P, Shih DQ, McGovern DP et al. Current concepts on the immunopathogenesis of inflammatory bowel disease. Front Biosci (Elite Ed) 2012; 4: 1451–1477.

2. Huang VW, Reich KM, Fedorak RN. Distance management of inflammatory bowel disease: Systematic review and meta-analysis. World J Gastroenterol 2014; 20 (3): 829–842. doi: 10.3748/wjg.v20.i3.829.

3. Berman M1, Fenaughty A. Technology and managed care: patient benefits of telemedicine in a rural health care network. Health Econ 2005; 14 (6): 559–573.

4. Krier M, Kaltenbach T, McQuaid K et al. Potential use of telemedicine to provide outpatient care for inflammatory bowel disease. Am J Gastroenterol 2011; 106 (12): 2063–2067. doi: 10.1038/ajg.2011. 329.

5. Capalbo SM, Heggem CN. Valuing rural health care: issues of access and quality. Am J Agri Econ 1999; 81: 674–670.

6. Barlow C, Cooke D, Mulligan K et al. A critical review of self-management and educational interventions in inflammatory bowel disease. Gastroenterol Nurs 2010; 33 (1): 11–18. doi: 10.1097/SGA.0b013e 3181ca03cc.

7. Siegel CA. Transforming gastroenterology care with telemedicine. Gastroenterology 2017; 152 (2): 958–963. doi: 10.1053/j.gastro.2017.01.048.

8. Romanko I, Lukáš M, Bortlík M. New approaches in follow-up of patients suffering from inflammatory bowel diseases. Gastroent Hepatol 2015; 69 (5): 441–448. doi: 10.14735/amgh2015441.

9. Surti B, Spiegel B, Ippoliti A et al. Assessing health status in inflammatory bowel disease using a novel single-item numeric rating scale. Dig Dis Sci 2013; 58 (5): 1313–1321. doi: 10.1007/s10620-012-2500-1.

10. Bodger K, Ormerod C, Shackcloth D et al. Development and validation of a rapid, generic measure of disease control from patient’s perspective: the IBD-control questionnaire. Gut 2014; 63 (7): 1092–1102. doi: 10.1136/gutjnl-2013-305600.

11. Keefer L, Kiebles JL, Taft TH et al. The role of self-efficacy in inflammatory bowel disease management: preliminary validation of a disease-specific measure. Inflamm Bowel Dis 2011; 17 (2): 614–620. doi: 10.1002/ibd.21314.

12. Alrubaiy L, Rikaby I, Dodds P et al. Systematic review of health-related quality of life measures for imflammatory bowel diseases. J Crohn Colitis 2015; 9 (3): 284–292. doi: 10.1093/ecco-jcc/jjv002.

13. Elkjaer M. E-health: Web-guided ther-apy and disease self-management in ulcerative colitis. Impact on disease outcome, quality of life and compliance. Dan Med J 2012; 59 (7): B4478.

14. Kim ES, Park KS, Cho KB et al. Development of a web-based, self-reporting symptom diary for Crohn’s disease, and its correlation with the Crohn’s Disease Activity Index: web-based, self-reporting symptom diary for Crohn’s disease. J Crohns Colitis 2014; pii: S1873-9946[14]00268-2. doi: 10.1016/j.crohns.2014.09.003.

15. Jackson BD, Gray K, Knowles SR et al. EHealth Technologies in Inflammatory Bowel Disease: A Systematic Review. J Crohns Colitis 2016; 10 (9): 1103–1121. doi: 10.1093/ecco-jcc/jjw059.

16. Pedersen N, Thielsen P, Martinsen L et al. eHealth: individualization of mesalazine treatment through a self-managed web-based solution in mild-to-moderate ulcerative collitis. Inflamm Bowel Dis 2014; 20 (12): 2276–2285. doi: 10.1097/MIB.0000000000000199.

17. Pedersen N, Elkjaer M, Duricova D et al. eHealth: individualisation of infliximab treatment and disease course via a self-managed web-based solution in Crohn’s disease. Aliment Pharmacol Ther 2012; 36 (9): 840–849.

18. Mc Combie A, Gearry R, Andrews J et al. Does Computerized Cognitive Behavioral Therapy Help People with Inflammatory Bowel Disease? A Randomized Controlled Trial. Inflamm Bowel Dis 2016; 22 (1): 171–181. doi: 10.1097/MIB. 0000000000000567.

19. Calafat M, Cabré E, Mañosa M et al. High within-day variability of fecal calprotectin levels in patients with active ulcerative colitis: what is the best timing for stool sampling? Inflamm Bowel Dis 2015; 21 (5): 1072–1076. doi: 10.1097/MIB.0000000 000000349.

20. Webster K, Odom L, Peterman A et al. The Functional Assessment of Chronic Ill-ness Therapy (FACIT) measurement system: Validation of version 4 of the core questionnaire. Qual Life Res 1999; 8: 604.

21. Johnson M, Lithgo K, Price T. IBD-SSHAMP (Supported, Self help and Management Programme); UK’s first Internet based Remote Management System for Managing Stable IBD. Gut 2013; 62: A34–A35. Abstract OC-080.

22. Hunter J, Claridge A, James S et al. Improving outpatient services: the Southampton IBD virtual clinic. Postgrad Med J 2012; 88 (1042): 487–491. doi: 10.1136/ postgradmedj-2012-100123rep.

23. Lichtenstein GR, Rubin D. Gastroenterology Virtual clinic. [online]. Available from: http: //ibdvirtualclinic.com/.

24. ISD Scotland. SMR Datasets, Virtual clinic. [online]. Available from: www.ndc.scot.nhs.uk.

25. Hommel KA, Hente E, Herzer M et al. Telehealth behavioral treatment for medication nonadherence: a pilot and feasibility study. Eur J Gastroenterol Hepatol 2013; 25 (4): 469–473. doi: 10.1097/MEG.0b013e 32835c2a1b.

26. Krier M, Kaltenbach T, McQuaid K et al. Potential use of telemedicine to provide outpatient care for inflammatorz bowel disease. Am J Gastroenterol 2011; 106 (12): 2063–2067. doi: 10.1038/ajg.2011.329.

27. Con D, De Cruz P. Mobile phone apps for inflammatory bowel disease self-management: A systematic assessment of content and tools. JMIR Mhealth Uhealth 2016; 4 (1): e13. doi: 10.2196/mhealth.4874.

28. Cross RK, JAmbaulikar G, Langenberg P et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD): Design and implementation of randomized clinical trial. Contemp Clin Trials 2015; 42: 132–144. doi: 10.1016/j.cct.2015.03.006.

29. Atreja A, Khan S, Rogers JD et al. Impact of th Mobile HealthPROMISE platform on the quality of care and quality of life in patients with inflammatory bowel disease: study protocol of pragmatic randomized controlled trial. JMIR Res Protoc 2015; 4 (1): e23. doi: 10.2196/resprot.4042.

30. Plener I, Hayward A, Saibil F. E-mail communication in the management of gastroenterology patients: a review. Can J Gastroenterol Hepatol 2014; 28 (3): 161–165.

31. Aguas Peris M, Del Hoyo J, Bebia P et al. Telemedicine in inflammatory bowel disease: opportunities and approaches. Inflamm Bowel Dis 2015; 21 (2): 392–399. doi: 10.1097/MIB.0000000000000241.

32. Van Deen WK, van der Meulen-de Jong AE, Parekh NK et al. Development and Validation of an Inflammatory Bowel Diseases Monitoring Index for Use With Mobile Health Technologies. Clin Gastroenterol Hepatol 2015; 14 (12): 1742–1750. doi: 10.1016/j.cgh.2015.10.035.

33. Marín-Jiménez I, Nos P, Domènech E et al. Diagnostic Performance of the Simple Clinical Colitis Activity Index Self-Administered Online at Home by Patients With Ulcerative Colitis: CRONICA-UC Study. Am J Gastroenterol 2016; 111 (2): 261–268. doi: 10.1038/ajg.2015.403.

34. Heida A, Dijkstra A, Groen H et al. Comparing the efficacy of a web-assisted calprotectin-based treatment algorithm (IBD-live) with usual practices in teenagers with inflammatory bowel disease: study protocol for a randomized controlled trial. Trials 2015; 16: 271. doi: 10.1186/s13063-015-0787-x.

35. Annese V, Daperno M, Rutter MD et al. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis 2013; 7 (12): 982–1018. doi: 10.1016/j.crohns.2013.09.016.

36. de Jong M, van der Meulen-de Jong A, Romberg-Camps M et al. Development and Feasibility Study of a Telemedicine Tool for All Patients with IBD: MyIBDcoach. Inflamm Bowel Dis 2017; 23 (4): 485–493. doi: 10.1097/MIB.0000000000001034.

37. Vinding KK, Elsberg H, Thorkilgaard T et al. Fecal calprotectin measured by patiens at home using smartphones – a new clinical tool in monitoring patiens with inflammatory bowel disease. Inflamm Bowel Dis 2016; 22 (2): 336–344. doi: 10.1097/MIB.0000000000000619.

38. Peyrin-Biroulet L, Sandborn W, Sands BE et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): Determining therapeutic goals for treat-to-target. Am J Gastroenterol 2015; 110 (9): 1324–1338. doi: 10.1038/ajg.2015.233.